The main focus of the Genomics Shared Resource (GSR) is to provide expertise and comprehensive service in the area of microarray- and next-generation sequencing (NGS)-based genomics research in both a highly accessible and cost-effective manner for Cancer Center members. The GSR, originally named as the Gene Expression Resource, has been an active Shared Resource in the Cancer Center since the first application for NCI designation in 2001. Since then, we have expanded our portfolio of services to encompass nearly every level of genomics ranging from analysis of cancer genomes with single-base resolution up through standard mRNA and miRNA expression profiling. These also include single nucleotide polymorphism genotyping, epigenomics, and analyses for transcript splice variants, fusion genes, and genomic instability. The GSR has strived to provide our researchers with direct access to the most contemporary genomic applications and state-of-the-art instrumentation. Towards this goal, we possess the capacity to perform profiling on most of the common commercially-available microarray platforms (e.g., Affymetrix, Agilent, lllumina) as well as custom-designed ones. Having recently acquired an lllumina Genome Analyzer llx NGS system, the GSR now also provides this exciting state-of-the-art profiling technology. Importantly, all of these applications can be utilized for translational research as a result of our development of optimized protocols for the analysis of samples from a broad range of sources and of extremely limited amounts. To complement these services and to help achieve productive outcomes from genomics experiments, the GSR also provides extensive data analysis and integrative bioinformatics support and routinely assists in the preparation of the appropriate sections of manuscripts and grant proposals. Taken together, the GSR provides a complete integrative and functional molecular profiling solution to the Cancer Center.
This resource provides leading technologies for the analysis of genes, gene expressions, and DNA-related, cellular material used in examining cancer cells and comparing them to normal cells to gain insights into the cellular processes, events, and materials implicated in cancer. Thus it improves the scientific quality of cancer research and ultimately the development of more effective cancer therapies.
|Seo, Jai Woong; Tavaré, Richard; Mahakian, Lisa M et al. (2018) CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res 24:4976-4987|
|Yuan, Ye; He, Yixuan; Bo, Ruonan et al. (2018) A facile approach to fabricate self-assembled magnetic nanotheranostics for drug delivery and imaging. Nanoscale 10:21634-21639|
|Knight, Jennifer F; Sung, Vanessa Y C; Kuzmin, Elena et al. (2018) KIBRA (WWC1) Is a Metastasis Suppressor Gene Affected by Chromosome 5q Loss in Triple-Negative Breast Cancer. Cell Rep 22:3191-3205|
|Xue, Xiangdong; Huang, Yee; Bo, Ruonan et al. (2018) Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment. Nat Commun 9:3653|
|Dou, John; Schmidt, Rebecca J; Benke, Kelly S et al. (2018) Cord blood buffy coat DNA methylation is comparable to whole cord blood methylation. Epigenetics 13:108-116|
|Couto, K M; Moore, P F; Zwingenberger, A L et al. (2018) Clinical characteristics and outcome in dogs with small cell T-cell intestinal lymphoma. Vet Comp Oncol 16:337-343|
|Xue, Xiangdong; Huang, Yee; Wang, Xinshuai et al. (2018) Self-indicating, fully active pharmaceutical ingredients nanoparticles (FAPIN) for multimodal imaging guided trimodality cancer therapy. Biomaterials 161:203-215|
|Ho, Pui Yan; Duan, Zhijian; Batra, Neelu et al. (2018) Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy. J Pharmacol Exp Ther 365:494-506|
|Zuo, Yang; Qi, Jinyi; Wang, Guobao (2018) Relative Patlak plot for dynamic PET parametric imaging without the need for early-time input function. Phys Med Biol 63:165004|
|McGee, Heather M; Daly, Megan E; Azghadi, Sohelia et al. (2018) Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. Int J Radiat Oncol Biol Phys 101:1259-1270|
Showing the most recent 10 out of 836 publications